Search

Your search keyword '"Sorrentino, Paolo"' showing total 4 results
Start Over Author "Sorrentino, Paolo" Journal world journal of gastroenterology
4 results on '"Sorrentino, Paolo"'

3. Sorafenib and entecavir: the dioscuri of treatment for advanced hepatocellular carcinoma?

Author

D'Angelo S, Secondulfo M, De Cristofano R, and Sorrentino P

Subjects
Aged, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular virology, Female, Guanine therapeutic use, Hepatitis B complications, Hepatitis B diagnosis, Hepatitis B mortality, Humans, Liver Neoplasms mortality, Liver Neoplasms pathology, Liver Neoplasms virology, Male, Middle Aged, Neoplasm Staging, Niacinamide therapeutic use, Sorafenib, Time Factors, Treatment Outcome, Antineoplastic Agents therapeutic use, Antiviral Agents therapeutic use, Carcinoma, Hepatocellular drug therapy, Guanine analogs & derivatives, Hepatitis B drug therapy, Liver Neoplasms drug therapy, Niacinamide analogs & derivatives, Phenylurea Compounds therapeutic use, Protein Kinase Inhibitors therapeutic use
Abstract

Hepatitis B virus (HBV) is responsible for 50%-80% of cases of hepatocellular carcinoma (HCC) worldwide. Entecavir (ET) is a potent inhibitor of chronic HBV-DNA polymerase, inhibiting both the priming and elongation steps of viral DNA replication. Sorafenib (SO) has proven efficacy in prolonging survival in patients with advanced HCC. In this frontier report we discuss a possible way to optimize treatment outcomes in patients with HBV and HCC by treatment with ET and SO, on the basis of our practice and published evidence from the literature.

Published
2013
Full Text
View/download PDF

4. Flow cytometry assay of myeloid dendritic cells (mDCs) in peripheral blood during acute hepatitis C: possible pathogenetic mechanisms.

Author

Perrella A, Atripaldi L, Bellopede P, Patarino T, Sbreglia C, Tarantino G, Sorrentino P, Conca P, Ruggiero L, and Perrella O

Subjects
Acute Disease, Adult, Antiviral Agents therapeutic use, CD11 Antigens analysis, Case-Control Studies, Cell Count, Disease Progression, Drug Combinations, Female, Hepatitis A blood, Hepatitis A drug therapy, Hepatitis A etiology, Hepatitis A immunology, Hepatitis C drug therapy, Hepatitis C immunology, Humans, Interferons therapeutic use, Lipopolysaccharide Receptors analysis, Male, Middle Aged, Ribavirin therapeutic use, Dendritic Cells immunology, Flow Cytometry, Hepatitis C blood, Hepatitis C etiology, Myeloid Cells immunology
Abstract

Aim: To asses the expression of myeloid dendritic cells (CD11c+) subset during acute HCV hepatitis and its possible involvement in natural history of the infection., Methods: We enrolled 11 patients with acute hepatitis C (AHC) (Group A), 10 patients with acute hepatitis A (AHA) (as infective control-Group B) and 10 healthy donors (group C) in this study. All patients underwent selective flow cytometry gating strategies to assess the peripheral number of the myeloid dendritic cells (mDCs) to understand the possible role and differences during acute hepatitis., Results: Eight of 11 patients with acute HCV hepatitis did not show any increase of mDCs compared to healthy individuals, while a significant decrease of mDCs was found in absolute cell count (z = -2.37; P<0.05) and percentage (z = -2.30; P<0.05) as compared with AHA. On the contrary, The remaining three patients of the group A had a higher mDCs number and percentage as occur in group B. Interestingly, after six months, those patients did not show any increase of mDCs subset were chronically infected. while the three subjects with an increase of peripheral mDCs, as in HAV acute infection, resolved the illness., Conclusion: The lack of increase of mDCs during acute hepatitis C might be an important factor involved in chronicization of the infection.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results